Systematic Analysis of the Expression and Prognosis Relevance of FBXO Family Reveals the Significance of FBXO1 in Human Breast Cancer

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2021 Feb 24

PMID 33622332

Citations 24

Authors

Yaqian Liu

Bo Pan

Weikun Qu

Yilong Cao

Jun Li

Haidong Zhao

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer (BC) remains a prevalent and common form of cancer with high heterogeneity. Making efforts to explore novel molecular biomarkers and serve as potential disease indicators, which is essential to effectively enhance the prognosis and individualized treatment of BC. FBXO proteins act as the core component of E3 ubiquitin ligase, which play essential regulators roles in multiple cellular processes. Recently, research has indicated that FBXOs also play significant roles in cancer development. However, the molecular functions of these family members in BC have not been fully elucidated.

Methods: In this research, we investigated the expression data, survival relevance and mutation situation of 10 FBXO members (FBXO1, 2, 5, 6, 16, 17, 22, 28, 31 and 45) in patients with BC from the Oncomine, GEPIA, HPA, Kaplan-Meier Plotter, UALCAN and cBioPortal databases. The high transcriptional levels of FBXO1 in different subtypes of BC were verified by immunohistochemical staining and the specific mutations of FBXO1 were obtained from COSMIC database. Top 10 genes with the highest correlation to FBXO1 were identified through cBioPortal and COXPRESdb tools. Additionally, functional enrichment analysis, PPI network and survival relevance of FBXO1 and co-expressed genes in BC were obtained from DAVID, STRING, UCSC Xena, GEPIA, bc-GenExMiner and Kaplan-Meier Plotter databases. FBXO1 siRNAs were transfected into MCF-7 and MDA-MB-231 cell lines. Expression of FBXO1 in BC cell lines was detected by western-blot and RT-qPCR. Cell proliferation was detected by using CCK-8 kit and colony formation assay. Cell migration was detected by wound-healing and transwell migration assay.

Results: We found that FBXO2, FBXO6, FBXO16 and FBXO17 were potential favorable prognostic factors for BC. FBXO1, FBXO5, FBXO22, FBXO28, FBXO31 and FBXO45 may be the independent poor prognostic factors for BC. All of them were correlated to clinicopathological staging. Moreover, knockdown of FBXO1 in MCF7 and MDA-MB-231 cell lines resulted in decreased cell proliferation and migration in vitro. We identified that FBXO1 was an excellent molecular biomarker and therapeutic target for different molecular typing of BC.

Conclusion: This study implies that FBXO1, FBXO2, FBXO5, FBXO6, FBXO16, FBXO17, FBXO22, FBXO28, FBXO31 and FBXO45 genes are potential clinical targets and prognostic biomarkers for patients with different molecular typing of BC. In addition, the overexpression of FBXO1 is always found in breast cancer and predicts disadvantageous prognosis, implicating it could as an appealing therapeutic target for breast cancer patients.

Citing Articles

Construction and validation of immune-associated lncRNA model for predicting immune status and therapeutic reactions of triple-negative breast cancer.

Liu Y, Zhang M, Sun J, Zhang J, Gu B, Li J Am J Transl Res. 2024; 16(9):4355-4378.

PMID: 39398616 PMC: 11470336. DOI: 10.62347/VIXN9362.

FBXO family genes promotes hepatocellular carcinoma via ubiquitination of p53.

Gong Q, Zhang L, Guo J, Zhao W, Zhou B, Yang C J Cancer Res Clin Oncol. 2024; 150(10):458.

PMID: 39397119 PMC: 11471714. DOI: 10.1007/s00432-024-05948-3.

Decreased Expression of CD247 and CD4 Immune Marker Predicts Poor Prognosis in Triple Negative Breast Cancer.

Pateriya A, Nema R, Mishra A, Kumar A, Shrivastava A Asian Pac J Cancer Prev. 2024; 25(9):3187-3197.

PMID: 39342598 PMC: 11700313. DOI: 10.31557/APJCP.2024.25.9.3187.

IBSP Promotes Breast Cancer Bone Metastasis and Proliferation via BMP-SMAD Signaling Pathway.

Ding W, Lv D, Wang M, Pei D Cancer Rep (Hoboken). 2024; 7(8):e2153.

PMID: 39118232 PMC: 11310091. DOI: 10.1002/cnr2.2153.

METTL16 regulates the mRNA stability of FBXO5 via m6A modification to facilitate the malignant behavior of breast cancer.

Wang R, Gao X, Xie L, Lin J, Ren Y Cancer Metab. 2024; 12(1):22.

PMID: 39061113 PMC: 11282785. DOI: 10.1186/s40170-024-00351-5.

References

Peschiaroli A, Scialpi F, Bernassola F, Pagano M, Melino G . The F-box protein FBXO45 promotes the proteasome-dependent degradation of p73. Oncogene. 2009; 28(35):3157-66. PMC: 3865854. DOI: 10.1038/onc.2009.177. View

Ge M, Zhang N, Xia L, Zhang C, Dong S, Li Z . FBXO22 degrades nuclear PTEN to promote tumorigenesis. Nat Commun. 2020; 11(1):1720. PMC: 7136256. DOI: 10.1038/s41467-020-15578-1. View

Radvanyi L, Singh-Sandhu D, Gallichan S, Lovitt C, Pedyczak A, Mallo G . The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. Proc Natl Acad Sci U S A. 2005; 102(31):11005-10. PMC: 1182410. DOI: 10.1073/pnas.0500904102. View

Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H . Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008; 14(5):518-27. DOI: 10.1038/nm1764. View

Karnoub A, Dash A, Vo A, Sullivan A, Brooks M, Bell G . Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007; 449(7162):557-63. DOI: 10.1038/nature06188. View

Suber T, Nikolli I, OBrien M, Londino J, Zhao J, Chen K . FBXO17 promotes cell proliferation through activation of Akt in lung adenocarcinoma cells. Respir Res. 2018; 19(1):206. PMC: 6203195. DOI: 10.1186/s12931-018-0910-0. View

Paul D, Islam S, Manne R, Dinesh U, Malonia S, Maity B . F-box protein FBXO16 functions as a tumor suppressor by attenuating nuclear β-catenin function. J Pathol. 2019; 248(3):266-279. PMC: 6619347. DOI: 10.1002/path.5252. View

Forbes S, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J . COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 2016; 45(D1):D777-D783. PMC: 5210583. DOI: 10.1093/nar/gkw1121. View

Hsu J, Reimann J, Sorensen C, Lukas J, Jackson P . E2F-dependent accumulation of hEmi1 regulates S phase entry by inhibiting APC(Cdh1). Nat Cell Biol. 2002; 4(5):358-66. DOI: 10.1038/ncb785. View

10.

Shang Y, Brown M . Molecular determinants for the tissue specificity of SERMs. Science. 2002; 295(5564):2465-8. DOI: 10.1126/science.1068537. View

11.

Cepeda D, Ng H, Sharifi H, Mahmoudi S, Cerrato V, Fredlund E . CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer. EMBO Mol Med. 2013; 5(7):1067-86. PMC: 3721474. DOI: 10.1002/emmm.201202341. View

12.

Smoot M, Ono K, Ruscheinski J, Wang P, Ideker T . Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2010; 27(3):431-2. PMC: 3031041. DOI: 10.1093/bioinformatics/btq675. View

13.

Gutgemann I, Lehman N, Jackson P, Longacre T . Emi1 protein accumulation implicates misregulation of the anaphase promoting complex/cyclosome pathway in ovarian clear cell carcinoma. Mod Pathol. 2008; 21(4):445-54. DOI: 10.1038/modpathol.3801022. View

14.

Zhao Y, Tang Q, Ni R, Huang X, Wang Y, Lu C . Early mitotic inhibitor-1, an anaphase-promoting complex/cyclosome inhibitor, can control tumor cell proliferation in hepatocellular carcinoma: correlation with Skp2 stability and degradation of p27(Kip1). Hum Pathol. 2012; 44(3):365-73. DOI: 10.1016/j.humpath.2012.03.030. View

15.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

16.

Lu T, Chen D, Wang Y, Sun X, Li S, Miao S . Identification of DNA methylation-driven genes in esophageal squamous cell carcinoma: a study based on The Cancer Genome Atlas. Cancer Cell Int. 2019; 19:52. PMC: 6404309. DOI: 10.1186/s12935-019-0770-9. View

17.

Rey-Vargas L, Mejia-Henao J, Sanabria-Salas M, Serrano-Gomez S . Effect of neoadjuvant therapy on breast cancer biomarker profile. BMC Cancer. 2020; 20(1):675. PMC: 7368678. DOI: 10.1186/s12885-020-07179-4. View

18.

Zhao Q, Li H, Zhu L, Hu S, Xi X, Liu Y . Bioinformatics analysis shows that TOP2A functions as a key candidate gene in the progression of cervical cancer. Biomed Rep. 2020; 13(4):21. PMC: 7403841. DOI: 10.3892/br.2020.1328. View

19.

Shapira M, Kakiashvili E, Rosenberg T, Hershko D . The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells. Breast Cancer Res. 2006; 8(4):R46. PMC: 1779462. DOI: 10.1186/bcr1533. View

20.

Lignitto L, LeBoeuf S, Homer H, Jiang S, Askenazi M, Karakousi T . Nrf2 Activation Promotes Lung Cancer Metastasis by Inhibiting the Degradation of Bach1. Cell. 2019; 178(2):316-329.e18. PMC: 6625921. DOI: 10.1016/j.cell.2019.06.003. View